Stealth start-up Quench among teams tying protein to inflammatory cell death

Atlas Venture-backed start-up Quench Bio has partnered with a Max Planck Institute for Infection Biology team to target an inflammatory cell death pathway implicated in inflammatory and autoimmune diseases.

The company, which is funded by Atlas and Arix Bioscience plc (LSE:ARIX), is developing compounds that inhibit highly inflammatory processes in the innate immune system with a focus on diseases such as non-alcoholic steatohepatitis (NASH), lupus and atherosclerosis, according to the LinkedIn profile of CEO Samantha Truex...